Search - tctmd.com

Displaying 1 - 20 of 32

Sort: Relevancy | Date

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

News Conference News TCT 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

October 27, 2025

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

News Conference News TCT 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

November 01, 2024

QFR No Match for FFR in Guiding Revascularizations: FAVOR III Europe

News Conference News TCT 2024

QFR No Match for FFR in Guiding Revascularizations: FAVOR III Europe

October 30, 2024

TRISCEND II: Full Results a Win for TTVR in Severe Tricuspid Regurgitation

News Conference News TCT 2024

TRISCEND II: Full Results a Win for TTVR in Severe Tricuspid Regurgitation

Michael O'Riordan

October 30, 2024

ALIGN-AR at 2 Years Shows Promise for TAVI With Trilogy in Aortic Regurgitation

News Conference News TCT 2024

ALIGN-AR at 2 Years Shows Promise for TAVI With Trilogy in Aortic Regurgitation

Yael L. Maxwell

October 29, 2024

TRILUMINATE: More Patient Data Reassure on TEER’s Benefits for Severe TR

News Conference News TCT 2024

TRILUMINATE: More Patient Data Reassure on TEER’s Benefits for Severe TR

Michael O'Riordan

October 29, 2024

EARLY TAVR Breaks New Ground for Preemptive Treatment of Asymptomatic AS

News Conference News TCT 2024

EARLY TAVR Breaks New Ground for Preemptive Treatment of Asymptomatic AS

October 28, 2024

Sirolimus- and Paclitaxel-Coated Balloons Well-Matched for In-Stent Restenosis

News Conference News TCT 2023

Sirolimus- and Paclitaxel-Coated Balloons Well-Matched for In-Stent Restenosis

November 02, 2023

SCAAR Registry Delves Into Left Main Revascularization Outcomes

News Conference News TCT 2022

SCAAR Registry Delves Into Left Main Revascularization Outcomes

Michael O'Riordan

September 19, 2022

Ultrasound for Femoral Access? Neutral Results vs Common Sense: UNIVERSAL

News Conference News TCT 2022

Ultrasound for Femoral Access? Neutral Results vs Common Sense: UNIVERSAL

Yael L. Maxwell

September 19, 2022

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

News Conference News TCT 2022

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

Michael O'Riordan

September 19, 2022

Dedicated Catheter for Acute PE Shows Promise in IDE Trial

News Conference News TCT 2022

Dedicated Catheter for Acute PE Shows Promise in IDE Trial

September 17, 2022

News Conference News TCT 2021

Debating ISCHEMIA: Do the Results Apply to CABG, Too?

Michael O'Riordan

November 10, 2021

Transcatheter Mitral, Tricuspid Valve Replacement Inch Forward

News Conference News TCT 2021

Transcatheter Mitral, Tricuspid Valve Replacement Inch Forward

Yael L. Maxwell

November 06, 2021

More Complications With Plug Closure After TAVI: CHOICE-CLOSURE

News Conference News TCT 2021

More Complications With Plug Closure After TAVI: CHOICE-CLOSURE

Michael O'Riordan

November 05, 2021

TAVI Edges Out Surgery in 2-Year Costs for Low-risk Patients: PARTNER 3

News Conference News TCT 2021

TAVI Edges Out Surgery in 2-Year Costs for Low-risk Patients: PARTNER 3

Yael L. Maxwell

November 05, 2021

SURTAVI: Self-Expanding TAVI Valve Holds Up vs SAVR Through 5 Years

News Conference News TCT 2021

SURTAVI: Self-Expanding TAVI Valve Holds Up vs SAVR Through 5 Years

November 05, 2021

iFR Matches FFR Through 5 Years: iFR-SWEDEHEART

News Conference News TCT 2021

iFR Matches FFR Through 5 Years: iFR-SWEDEHEART

November 04, 2021

FAME 3: PCI Fails to Demonstrate Noninferiority to Surgery in Three-Vessel CAD

News Conference News TCT 2021

FAME 3: PCI Fails to Demonstrate Noninferiority to Surgery in Three-Vessel CAD

Michael O'Riordan

November 04, 2021

FlowTriever Safe, Effective for Acute PE in Expanded FLASH Results

News Conference News TCT 2021

FlowTriever Safe, Effective for Acute PE in Expanded FLASH Results

November 03, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.